BOME fluctuates 85.2% within 24 hours, reaching a peak of $0.000895: 180.9% surge in trading volume drives movement
Bitget Pulse2026/04/19 22:01Volatility Overview
BOME's price rebounded from a 24-hour low of $0.0004834 to a high of $0.000895, now quoted at $0.0005943, with a price swing of 85.2%. Trading volume reached $63.12 million, an increase of 180.9% over the previous period. There was a net capital outflow of about $64,000 (CEX net outflow of $61,000, DEX net outflow of $3,000). DEX liquidity is around $10.7 million, with a market cap of approximately $38.48 million.
Brief Analysis of Abnormal Movement Reasons
- No official announcements, major news events, or significant on-chain whale activities (such as large transactions) were found within the past 24 hours.
- Trading volume surged by 180.9% to $63.12 million, likely a direct driver, accompanied by a broad rebound in the Solana meme coin sector.
Market View and Outlook
Community trading on the X platform is active, with many traders sharing bullish setups, such as expected wave rises after trendline breakouts (targeting $0.000580-0.000630), or a continued move upward after holding key support. However, there are also reminders about the risks of chasing highs and potential pullbacks. The mainstream sentiment is cautiously optimistic, with focus on the $0.000533 support and capital flows.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.